GFACX
Price
$61.91
Change
-$1.33 (-2.10%)
Updated
Sep 6 closing price
NWZMX
Price
$17.66
Change
-$0.44 (-2.43%)
Updated
Sep 6 closing price
Ad is loading...

GFACX vs NWZMX

Header iconGFACX vs NWZMX Comparison
Open Charts GFACX vs NWZMXBanner chart's image
American Funds Growth Fund of Amer C
Price$61.91
Change-$1.33 (-2.10%)
VolumeN/A
CapitalizationN/A
Nationwide Loomis All Cap Gr R6
Price$17.66
Change-$0.44 (-2.43%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GFACX vs NWZMX Comparison Chart
Loading...
VS
GFACX vs. NWZMX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFACX is a Buy and NWZMX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 270B vs. NWZMX (191M). GFACX (0.00) and NWZMX (0.00) have matching dividends . GFACX was incepted earlier than NWZMX: GFACX (24 years) vs NWZMX (7 years). GFACX is a more actively managed with annual turnover of: 31.00 vs. NWZMX (12.63). GFACX has a lower initial minimum investment than NWZMX: GFACX (250) vs NWZMX (1000000). GFACX annual gain was more profitable for investors over the last year : 16.44 vs. NWZMX (14.70). NWZMX return over 5 years is better than : 47.79 vs. GFACX (38.56).
GFACXNWZMXGFACX / NWZMX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years7 years-
Gain YTD14.98215.06799%
Front LoadN/AN/A-
Min. Initial Investment25010000000%
Min. Initial Investment IRAN/AN/A-
Net Assets270B191M141,361%
Annual Yield % from dividends0.000.00-
Returns for 1 year16.4414.70112%
Returns for 3 years-11.08-8.59129%
Returns for 5 years38.5647.7981%
Returns for 10 years42.46N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KW11.040.03
+0.27%
Kennedy-Wilson Holdings
CTVA55.11-0.39
-0.70%
Corteva
FIVN29.58-0.24
-0.80%
Five9
VEV0.14N/A
-1.68%
Vicinity Motor Corp
ADAP1.11-0.05
-4.31%
Adaptimmune Therapeutics plc